<DOC>
	<DOCNO>NCT02721953</DOCNO>
	<brief_summary>Butyrate short chain fatty acid ( SCFA ) produce bacterial fermentation undigested starch gut . Butyrate carry different effect intestinal extraintestinal level , include : immune regulation anti-inflammatory effect intestinal systemic level modulation gut microbiota . Many effect result epigenetic mechanism . Shown animal model obesity induce high fat diet ( HFD ) , butyrate exercise effective protective action obesity stimulation intestinal satiety hormone . Shown always murine model obesity induce HFD , butyrate effective prevent treat obesity insulin resistance . After 5 week treatment butyrate observe reduction 10.2 % body weight , 30 % fast glucose 50 % insulin resistance . In animal model metabolic syndrome NAFLD researcher recently demonstrate administration butyrate able significantly reduce insulin resistance , liver damage , dyslipidaemia modulation inflammatory process . Pharmacokinetic pharmacodynamic study humans show oral administration butyrate safe well tolerate . The peak serum level occur 4-6 hour oral administration . All data make plausible possible positive effect insulin resistance obese child .</brief_summary>
	<brief_title>The Effects Butyrate Children With Obesity</brief_title>
	<detailed_description />
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Butyric Acid</mesh_term>
	<criteria>Obesity ( BMI &gt; 95° percentile ) HOmeostasis Model Assessment ( HOMAIR ) &gt; 4 ( obtain calculate product fast plasma insulin express microunits/mL fasting plasma glucose express mmol/L divide 22.5 ) Age &lt; 10 &gt; 15 year BMI &lt; 95° centile HOMAIR &lt; 4 Patients pharmacological treatment obesity ( metformin ) take vitamin E , pre , pro synbiotics Simultaneous presence chronic disease unrelated obesity ( cancer , immunodeficiency , cystic fibrosis , allergy , celiac disease , autoimmune disease , neuropsychiatric disorder , type 1 diabetes , inflammatory bowel disease , malformation urinary gastrointestinal respiratory tract , chronic lung disease , genetic metabolic disease , chronic hematological disease ) History surgery treatment obesity Any medical condition may interfere participation study Participation clinical trial still progress</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>